Royalty Pharma Acquires Ibrutinib Royalty Rights for $485 Million In Cash

New York, NY – July 18, 2013 - Royalty Pharma announced today that it has acquired certain rights to receive royalties on future sales of drug candidate ibrutinib from Quest Diagnostics for $485 million in cash.

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.